Simcere Pharmaceutical Group Limited (Simcere Pharma) submitted a Next Day Disclosure Return dated 21 May 2026 detailing recent share repurchase activity and the company’s latest capital structure.

Key developments

1. Share capital status • Outstanding ordinary shares remained at 2,595.70 million as of 21 May 2026. • No treasury shares were held, and no new shares were issued during the period covered by the filing.

2. Aggregate repurchases pending cancellation • Between 12 January and 21 May 2026, Simcere Pharma repurchased 26.67 million shares for cancellation, equivalent to 1.08 % of the issued share base on the date the mandate was granted (13 June 2025). • Repurchase prices ranged from HKD 10.52 to HKD 11.83 per share, implying a total cash outlay of approximately HKD 294–316 million based on disclosed volume-weighted averages. • The latest transaction occurred on 21 May 2026, when 476,000 shares were bought back on-market at an average price of HKD 10.63, costing HKD 5.02 million.

3. Repurchase mandate utilisation • The board is authorised to repurchase up to 247.47 million shares. • After the 26.67 million shares already bought, 220.80 million shares (about 89 % of the mandate) remain available.

4. Moratorium on new issuance • In line with Main Board Rule 10.06(3)(a), Simcere Pharma is restricted from issuing new shares until 20 June 2026, 30 days after the most recent repurchase.

All repurchase transactions were executed on the Hong Kong Stock Exchange and certified by the company as compliant with the Listing Rules and applicable regulations.